By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    stress management for healthcare workers
    3 Tips For Healthcare Professionals: How To Stay Beautiful, Healthy, and Happy
    November 2, 2021
    importance of relaxing on the weekend for your health
    Importance of Relaxing During the Weekend for Optimal Health
    March 25, 2022
    LASIK Eye Surgery
    What Is LASIK Eye Surgery?
    May 16, 2022
    Latest News
    6 Essential Strategies for Improving Your Medical Practice
    January 25, 2023
    Staying Positive While Living with Mesothelioma
    January 24, 2023
    The Many Health Benefits of Being Outdoors
    January 17, 2023
    How to Assess a Safe Placement of a Nasogastric or Nasoenteric Tube and Its Complications
    January 19, 2023
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Massachusetts Gets Ready to Tame HealthCare Costs
    April 14, 2013
    ObamaCare and Tax Evasion
    August 14, 2013
    Maslow
    Improving Clinical Outcomes by Addressing Social and Basic Needs
    April 17, 2014
    Latest News
    Simplifying the Genetic Testing Process: How At-Home Kits are Changing the Game
    January 25, 2023
    9 Hospitals That Have Introduced Green Initiatives
    January 25, 2023
    Why a Health Retreat Can Be the Best Medicine
    January 12, 2023
    Best Money-Saving Tips for Health Managers
    January 12, 2023
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Regulation of Wound Management Products
Share
Sign In
Notification Show More
Latest News
Personal Injury Healing Tips and Strategies
Personal Injury Healing Tips and Strategies
Health
ABA therapist
Everything You Need to Know About Applied Behavior Analysis
Health
Small Lifestyle Changes That Can Have A Big Impact On Your Well-Being
lifestyle Wellness
The Future Of Medicine: How Immunotherapy Is Saving Lives
The Future Of Medicine: How Immunotherapy Is Saving Lives
Technology
medical practice and technology advancement
6 Essential Strategies for Improving Your Medical Practice
Technology
Aa
Health Works CollectiveHealth Works Collective
Aa
Search
Have an existing account? Sign In
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Regulation of Wound Management Products
BusinessTechnology

Regulation of Wound Management Products

PatrickDriscoll
Last updated: 2011/12/11 at 8:26 AM
PatrickDriscoll
Share
7 Min Read
SHARE

The passage below is from the MedMarket Diligence Report #S247, “Worldwide Wound Management, 2008-2017: Established and Emerging Products, Technologies and Markets in the U.S., Europe, Japan and Rest of World.”

The passage below is from the MedMarket Diligence Report #S247, “Worldwide Wound Management, 2008-2017: Established and Emerging Products, Technologies and Markets in the U.S., Europe, Japan and Rest of World.”

A wide range of regulatory approval conditions is applied to wound management products. The decision about regulatory classification for a given wound management product lies with the regulatory authority of the country in which the product is to be marketed and the manufacturing site making the product comes within their jurisdiction by virtue of the intent to market the product.

In the USA, medical devices fall within one of three categories depending on the complexity of the product and the invasiveness of its application. Fabric dressings are simple and minimally invasive, and to are designated as Class I devices, whereas products containing biomaterials of human or animal origin are in Class III. Some products that may be considered as examples of “Advanced Wound Care” (AWC, an abbreviation that is used widely in this report, and is synonymous with “advanced wound management”) are classified as Class II.

Medical devices require an investigational device exemption for clinical evaluation in humans; they are regulated through and receive 510(k) approval through a pre-market approval scheme regulated by the FDA in the USA, and are approved through the CE Marking process which was introduced in the early 1990s in Europe. 

More Read

cybersecurity options for hospitals

Should Hospitals Use SASE or Traditional Network Security?

Patient Tracking Systems: Improving Facilities for Patients and Medical Staff
Building Telemedicine System: Features and Tips
The Technology and Services You Need to Open Your Own Counseling Office
5 Ways New Technology is Revolutionizing Health

Class I devices in Europe require development and manufacture to be performed under international standard quality control systems, and device dossiers to be managed by the manufacturing company. Class II devices require the dossiers to be submitted for review, and Class III devices require a more substantial device dossier to be compiled and submitted for review with more rigorous toxicological and clinical evaluation. In Europe, devices which incorporate biological materials derived from animals are classed automatically as Class III devices.

In the USA, pharmacological developments (with a pharmacologically active therapeutic benefit) automatically require an investigational new drug (IND) application. Biologic materials are reviewed for a biologics license application (BLA) through an IND by the CBER division of the FDA (CBER stands for Center for Biologic Evaluation and Research).

 

Wound-segments-2008-2017

General wound care products generally fall within the Class I or Class II device categories around the world; any products containing mammalian proteins are Class III devices. The route for approval of more sophisticated products, like those designed to deliver an active therapeutic endpoint, such as pharmaceuticals and tissue engineering products, is more complex and less consistent in different regions around the world.

A wide range of regulatory approval conditions are applied to cell-based therapy products. Many of the technical challenges associated with creating a new tissue-engineered product are focused on the clinical proof phase, the regulatory requirements associated with making, proving effectiveness and safety of the product, and a number of controls on product claims and usage. Often the approach to achieving regulatory approval seems to be arduous, inconsistent and arbitrary. This is best illustrated by the complexity of approval for new tissue engineered products that exist today.

Autologous products for skin are currently available in the USA and new approaches to offering these cells wrapped up in customized services are becoming prevalent around the world. Allogeneic cell-based products for treatment of burn victims, skin conditions, and chronic wound care are now approved from a small number of suppliers in the USA, and several more on their way around the world.

Autologous tissue and cells transplanted during surgery do not have any regulatory requirements placed upon them by the US FDA. However, the devices used to carry out the surgical procedure are regulated as Class I medical devices. These products are required to be manufactured under Good Manufacturing Practices; they are regulated as Devices, and require 510(k)s in the USA. In Europe they are Class I medical devices.

Donated cadaveric tissue products produced to aid surgical construction must be manufactured under Good Manufacturing Practices (GMP) with ATSB or FDA approved manufacturing in the USA, and require Pre-Market Application (PMA) in the USA if extensively processed between removal from donor and transplantation to recipient. These products are classified as Medical Devices. They require extensive infectious disease screening and testing, with procedures which closely control good handling practices.  They require pre-market approval as they represent a substantial risk due to risk of spreading infectious agents. These products fall under the Center for Biologic Evaluation and Research (CBER) in the USA, and are classified in Europe as Class III devices requiring a substantial and reviewed device dossier, as they contain biologically derived materials. Minimally manipulated products do not require a PMA. A number of companies such as LifeCell sell products in this category, and a number of other companies are developing products in this area.

Tissue engineered implants represent a broad category of materials from those that are substantially donated allogeneic tissue with cells removed, to those products that are completely biologically based such as follicle and placental cell infusions.

Synthetic products are Class II devices, requiring PMA approval and good manufacturing practices in the USA, and the equivalent CE Mark and Class II approval in Europe.

Biologically-derived products are approved through the mutual recognition process in Europe as biological pharmaceuticals and require PMA approval in the USA, and manufacture to good manufacturing practice standards. These products are regulated by the CBER in the USA as biologics requiring a Biologics License Application.


See the complete report description, table of contents and list of exhibits at link.

TAGGED: wound management

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
PatrickDriscoll December 11, 2011
Share this Article
Facebook Twitter Copy Link Print
Share
By PatrickDriscoll
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Previous Article Mobile Health Technology: Results of HIMSS Survey on Usage
Next Article 12 Ways to Health Holiday Song

Stay Connected

1.5k Followers Like
4.5k Followers Follow
2.8k Followers Pin
136k Subscribers Subscribe

Latest News

Personal Injury Healing Tips and Strategies
Personal Injury Healing Tips and Strategies
Health January 28, 2023
ABA therapist
Everything You Need to Know About Applied Behavior Analysis
Health January 26, 2023
Small Lifestyle Changes That Can Have A Big Impact On Your Well-Being
lifestyle Wellness January 26, 2023
The Future Of Medicine: How Immunotherapy Is Saving Lives
The Future Of Medicine: How Immunotherapy Is Saving Lives
Technology January 26, 2023

You Might also Like

The Future Of Medicine: How Immunotherapy Is Saving Lives
Technology

The Future Of Medicine: How Immunotherapy Is Saving Lives

January 26, 2023
medical practice and technology advancement
Technology

6 Essential Strategies for Improving Your Medical Practice

January 25, 2023
green hospitals
Hospital Administration

9 Hospitals That Have Introduced Green Initiatives

January 20, 2023
saving money in healthcare
BusinessGlobal HealthcareHospital Administration

Best Money-Saving Tips for Health Managers

January 12, 2023
//

We influence million of users and is the most authentic source of information on healthcare business and technology news.

Quick Links

  • About
  • Contact
  • Privacy
Subscribe

Subscribe to our newsletter to get our newest articles instantly!

Follow US

© 2008-2023 HealthWorks Collective. All Rights Reserved.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?